Neuroblastoma is the third most common malignancy of childhood. Nowadays, MIBG has become a central procedure for staging and defining extent and location of neuroblastoma tumors. The recommendations of the International Neuroblastoma Staging System (INSS) indicate that MIBG scintigraphy must be performed in patients with neuroblastoma at the time of initial staging and as a followup tool durin...

Survival of patients with metastatic pheochromocytoma that have exceeded 30 years without therapy to reduce tumors have been reported. We reviewed the records of 38 patients with malignant pheochromocytoma who had received 131I-metaiodiobenzylguanidine (131I-MIBG) treatments between 1981 and 1996 to evaluate longevity. Survival from diagnosis to last follow-up exceeded 5 years in 21 of 38 (55%)...

The simultaneous distribution of monoclonal 131I-labeled anti-carcinoembryonic antigen (CEA) immunoglobulin (IgG) (NP-2) or 131I-labeled irrelevant myeloma IgG (Ag8) and [3H]thymidine was studied in hamsters bearing transplants of the GW-39 human colon carcinoma by qualitative double-tracer whole-body autoradiography. Autoradiography showed that large solid GW-39 tumors are characterized by het...

The daily administration of ƒÀ-estradiol benzoate (50ƒÊg or I mg) to hypophysectomized female rats for five consecutive days did not markedly alter 131I uptake by the thyroid gland. Estrogen or PMS increased thyroid uptake of 131I in TSH treated hypophysectomized rats. Similar results were obtained with estrogen but not PMS in hypophysectomized and oophorectomized animals. These observations sh...

BACKGROUND The loss of 131I uptake ability in metastases from differentiated thyroid carcinoma (DTC) is becoming a major obstacle in radioiodine treatment. However, there is no effective way to screen for 131I uptake ability in metastases. The identification of differentially expressed proteins by serum proteomics may contribute to our understanding of the mechanisms underlying the dedifferenti...

Accumulating evidence indicates that cancer stem cells (CSCs) are the cause of tumor drug/radio-resistance or distant metastasis; therefore, it is essential to eliminate CSCs to cure cancer completely. The purpose of this study was to utilize radioimmunotherapy (RIT) to target CD133(+) colonic CSCs and observe whether this prevented tumor development, by assessing the maximum tolerated dose (MT...

Radioimmunotherapy with 131I-labeled monoclonal immunoglobulins was studied using the Rauscher murine erythroleukemia. Tumor-specific monoclonal antibody, nonrelevant monoclonal antibody, F(ab')2 fragments, polyclonal gamma-globulin, and serum albumin were used as carriers of 131I. Therapeutic effects as measured by the reduction in splenomegaly were seen with all the radiolabeled proteins test...

The large numbers of studies on the postoperative management of differentiated thyroid carcinoma allows us to use adjuvant treatment and follow-up studies more selectively based on patient risk for recurrence and mortality. Recurrent differentiated thyroid carcinoma is more easily and more effectively treated with early diagnosis. With this in mind, patients who are at high risk for life-threat...

UNLABELLED 131I-labeled metaiodobenzylguanidine (MIBG) is an established treatment modality for neuroendocrine tumors. Because of low tumor doses, it has a predominantly palliative character. Our approach was to investigate whether intraarterial application of 131I-MIBG has the potential to enhance tumor uptake. METHODS Seventeen patients with primary or metastasized neuroendocrine tumors rec...